Clinical trials
Completed trials in Venezuela
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
158 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 6 |
| 2002 | 1 |
| 2003 | 10 |
| 2004 | 8 |
| 2005 | 5 |
| 2006 | 12 |
| 2007 | 11 |
| 2008 | 10 |
| 2009 | 22 |
| 2010 | 12 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 158 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 16 |
| Hoffmann-La Roche | 15 |
| AstraZeneca | 11 |
| Sanofi | 10 |
| Universidad Europea de Madrid | 9 |
| Bayer | 8 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 8 |
| Novartis | 7 |
| Pfizer | 7 |
| Hospital Universitario de Caracas | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 12 |
| Hypertension | 9 |
| Carpal Tunnel Syndrome | 8 |
| Diabetes Mellitus, Type 2 | 8 |
| Agnosia | 5 |
| Arthritis, Rheumatoid | 5 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Bipolar Disorder | 4 |
| Cardiovascular Diseases | 4 |
| Postoperative Pain | 4 |
Trials
Showing 26 to 50 of 158. Each trial links to its page on Pharma Observatory.
58 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.